ABVC
ABVC BioPharma, Inc.
Price Chart
Latest Quote
$1.89
Current Price| Previous Close | $2.02 |
| Open | $2.02 |
| Day High | $2.02 |
| Day Low | $1.86 |
| Volume | 49,448 |
Stock Information
| Shares Outstanding | 24.30M |
| Total Debt | $2.47M |
| Cash Equivalents | $257K |
| Revenue | $798K |
| Net Income | $-5.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $45.93M |
| EPS (TTM) | $-0.28 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 2/42| Debt to Equity | 1.98 |
| Debt to Earnings | 4.78 |
| Current Ratio | 0.33 |
| Quick Ratio | 0.22 |
| Avg Revenue Growth | 10.81% |
| Profit Margin | -962.12% |
| Return on Equity | -399.86% |
| Avg FCF Growth | -19.06% |
| FCF Yield | -3.94% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.89 | 49,448 |
| 2026-01-30 | $2.02 | 56,200 |
| 2026-01-29 | $2.08 | 65,300 |
| 2026-01-28 | $2.03 | 36,700 |
| 2026-01-27 | $2.06 | 48,400 |
| 2026-01-26 | $2.07 | 51,100 |
| 2026-01-23 | $2.06 | 44,000 |
| 2026-01-22 | $2.08 | 50,800 |
| 2026-01-21 | $2.05 | 76,500 |
| 2026-01-20 | $2.15 | 45,500 |
| 2026-01-16 | $2.02 | 43,200 |
| 2026-01-15 | $2.05 | 41,800 |
| 2026-01-14 | $2.08 | 58,600 |
| 2026-01-13 | $2.10 | 24,700 |
| 2026-01-12 | $2.08 | 94,400 |
| 2026-01-09 | $2.18 | 65,400 |
| 2026-01-08 | $2.25 | 19,600 |
| 2026-01-07 | $2.31 | 44,600 |
| 2026-01-06 | $2.27 | 22,000 |
| 2026-01-05 | $2.35 | 92,700 |
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $763 | $302,037 | $286,415 | $5,086 |
| Cost Of Revenue | $763 | $302,037 | $286,415 | $5,086 |
| Total Revenue | $509,589 | $152,430 | $969,783 | $355,797 |
| Operating Revenue | $509,589 | $152,430 | $969,783 | $355,797 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $825,899 | $1,313,671 | $293,968 | $227,210 |
| Total Expenses | $5,214,831 | $6,919,164 | $16,084,195 | $11,700,867 |
| Other Income Expense | $74,207 | $-129,914 | $-294,033 | $318,257 |
| Other Non Operating Income Expenses | $438,513 | $69,284 | $83,001 | $161,785 |
| Net Non Operating Interest Income Expense | $-738,541 | $-1,128,190 | $-106,151 | $-184,014 |
| Interest Expense Non Operating | $825,899 | $1,313,671 | $293,968 | $227,210 |
| Operating Expense | $5,214,068 | $6,617,127 | $15,797,780 | $11,695,781 |
| General And Administrative Expense | $5,034,796 | $5,554,211 | $13,104,323 | $11,052,874 |
| Other Operating Expenses | - | - | - | $-360,898 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 |
| Net Interest Income | $-738,541 | $-1,128,190 | $-106,151 | $-184,014 |
| Interest Income | $87,358 | $185,481 | $187,817 | $43,196 |
| Normalized Income | $-4,546,072 | $-7,630,684 | $-16,125,382 | $-12,953,038 |
| Net Income From Continuing And Discontinued Operation | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 |
| Total Operating Income As Reported | $-4,705,242 | $-6,766,734 | $-15,114,412 | $-11,705,968 |
| Net Income Common Stockholders | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 |
| Net Income | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 |
| Net Income Including Noncontrolling Interests | $-5,259,037 | $-8,280,844 | $-16,312,374 | $-12,035,851 |
| Net Income Continuous Operations | $-5,259,037 | $-8,280,844 | $-16,312,374 | $-12,035,851 |
| Pretax Income | $-5,369,576 | $-8,024,838 | $-15,514,596 | $-11,210,827 |
| Interest Income Non Operating | $87,358 | $185,481 | $187,817 | $43,196 |
| Operating Income | $-4,705,242 | $-6,766,734 | $-15,114,412 | $-11,345,070 |
| Gross Profit | $508,826 | $-149,607 | $683,368 | $350,711 |
| Special Income Charges | - | $0 | $-110,125 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.42 | $-1.80 | $-5.20 | $-5.10 |
| Basic EPS | $-0.42 | $-1.80 | $-5.20 | $-5.10 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-7,500 | $-41,832 | $-79,177 | $42,247 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,978,450 | $-6,131,579 | $-14,819,795 | $-11,128,096 |
| Total Unusual Items | $-364,306 | $-199,198 | $-377,034 | $156,472 |
| Total Unusual Items Excluding Goodwill | $-364,306 | $-199,198 | $-377,034 | $156,472 |
| Reconciled Depreciation | $200,921 | $380,390 | $23,799 | $11,993 |
| EBITDA (Bullshit earnings) | $-4,342,756 | $-6,330,777 | $-15,196,829 | $-10,971,624 |
| EBIT | $-4,543,677 | $-6,711,167 | $-15,220,628 | $-10,983,617 |
| Diluted Average Shares | $11,673,980 | $4,335,650 | $3,166,466 | $2,505,352 |
| Basic Average Shares | $11,673,980 | $4,335,650 | $3,166,466 | $2,505,352 |
| Diluted NI Availto Com Stockholders | $-4,902,878 | $-7,788,050 | $-16,423,239 | $-12,838,813 |
| Minority Interests | $356,159 | $492,794 | $-110,865 | $-802,962 |
| Tax Provision | $-110,539 | $256,006 | $797,778 | $825,024 |
| Gain On Sale Of Security | $-364,306 | $-199,198 | $-266,909 | $156,472 |
| Research And Development | $179,272 | $1,062,916 | $2,693,457 | $1,003,805 |
| Selling General And Administration | $5,034,796 | $5,554,211 | $13,104,323 | $11,052,874 |
| Other Gand A | $2,261,336 | $5,368,278 | $6,067,545 | $5,746,119 |
| Salaries And Wages | $2,773,460 | $185,933 | $7,036,778 | $5,306,755 |
| Write Off | - | $0 | $110,125 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $1,226,140 | $1,554,110 | $3,098,585 | $8,843,653 |
| Total Assets | $7,539,907 | $7,784,499 | $9,579,574 | $13,698,033 |
| Total Non Current Assets | $5,360,092 | $6,127,790 | $6,592,327 | $6,044,251 |
| Other Non Current Assets | $133,121 | $141,231 | - | - |
| Non Current Prepaid Assets | $1,816,742 | $1,966,742 | $3,032,551 | $1,313,621 |
| Investmentin Financial Assets | $790,250 | $847,252 | $842,070 | - |
| Current Assets | $2,179,815 | $1,656,709 | $2,987,247 | $7,653,782 |
| Other Current Assets | $96,213 | $101,051 | $150,235 | $528,354 |
| Restricted Cash | $615,433 | $656,625 | $1,306,463 | $736,667 |
| Receivables | $1,155,051 | $759,566 | $1,369,487 | $426,091 |
| Accounts Receivable | $0 | $1,530 | $98,325 | $280,692 |
| Allowance For Doubtful Accounts Receivable | $-616,414 | $-616,505 | - | - |
| Gross Accounts Receivable | $616,414 | $618,035 | - | - |
| Cash Cash Equivalents And Short Term Investments | $313,118 | $139,467 | $161,062 | $5,936,695 |
| Cash And Cash Equivalents | $248,382 | $60,155 | $85,265 | $5,828,548 |
| Non Current Deferred Assets | - | $0 | $117,110 | $981,912 |
| Non Current Deferred Taxes Assets | - | $0 | $117,110 | $981,912 |
| Non Current Accounts Receivable | - | $113,516 | $865,477 | $818,183 |
| Inventory | - | - | $0 | $25,975 |
| Goodwill And Other Intangible Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | $1,213,074 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $1,541,916 | $1,725,617 | $1,808,485 | - |
| Total Debt | $2,430,686 | $2,595,055 | $3,054,891 | $3,111,899 |
| Long Term Debt And Capital Lease Obligation | $236,807 | $407,457 | $791,827 | $1,124,799 |
| Current Debt And Capital Lease Obligation | $2,193,879 | $2,187,598 | $2,263,064 | $1,987,100 |
| Current Debt | $1,790,298 | $1,785,772 | $1,893,750 | $1,640,000 |
| Other Current Borrowings | $950,046 | $886,522 | - | $186,881 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $6,815,948 | $6,531,026 | $6,343,435 | $4,827,691 |
| Total Non Current Liabilities Net Minority Interest | $258,487 | $429,137 | $799,806 | $1,135,379 |
| Other Non Current Liabilities | $21,680 | $21,680 | $7,979 | $10,580 |
| Current Liabilities | $6,557,461 | $6,101,889 | $5,543,629 | $3,692,312 |
| Other Current Liabilities | $302,274 | $427,350 | $468,150 | - |
| Current Deferred Liabilities | $81,115 | $79,500 | $10,985 | $10,985 |
| Current Notes Payable | $30,000 | $0 | - | $0 |
| Payables And Accrued Expenses | $2,828,220 | $2,360,050 | $2,232,565 | $1,694,227 |
| Payables | $773,045 | $286,439 | $359,992 | $393,424 |
| Total Tax Payable | $0 | $112,946 | $0 | - |
| Accounts Payable | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $1,226,140 | $1,554,110 | $3,098,585 | $8,843,653 |
| Total Equity Gross Minority Interest | $723,959 | $1,253,473 | $3,236,139 | $8,870,342 |
| Stockholders Equity | $1,226,140 | $1,554,110 | $3,098,585 | $8,843,653 |
| Other Equity Interest | $31,040 | $-451,480 | $-1,354,440 | $-2,257,400 |
| Gains Losses Not Affecting Retained Earnings | $445,665 | $516,387 | $517,128 | $539,660 |
| Other Equity Adjustments | $445,665 | $516,387 | $517,128 | $539,660 |
| Retained Earnings | $-68,949,807 | $-64,046,929 | $-54,904,439 | $-38,481,200 |
| Long Term Equity Investment | $1,468,504 | $1,680,488 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $730,641 | $26,553 | $27,534 | - |
| Ordinary Shares Number | $13,137,843 | $7,913,745 | $3,285,732 | $2,892,632 |
| Share Issued | $13,868,484 | $7,940,298 | $3,313,266 | $2,892,632 |
| Tangible Book Value | $1,226,140 | $1,554,110 | $3,098,585 | $8,843,653 |
| Invested Capital | $3,016,438 | $3,339,882 | $4,992,335 | $10,483,653 |
| Working Capital | $-4,377,646 | $-4,445,180 | $-2,556,382 | $3,961,470 |
| Capital Lease Obligations | $640,388 | $809,283 | $1,161,141 | $1,471,899 |
| Total Capitalization | $1,226,140 | $1,554,110 | $3,098,585 | $8,843,653 |
| Minority Interest | $-502,181 | $-300,637 | $137,554 | $26,689 |
| Treasury Stock | $8,909,691 | $8,901,668 | $9,100,000 | $9,100,000 |
| Additional Paid In Capital | $78,595,065 | $73,978,380 | $67,937,050 | $58,113,667 |
| Capital Stock | $13,868 | $7,940 | $3,286 | $28,926 |
| Common Stock | $13,868 | $7,940 | $3,286 | $28,926 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $236,807 | $407,457 | $791,827 | $1,124,799 |
| Current Deferred Revenue | $81,115 | $79,500 | $10,985 | $10,985 |
| Current Capital Lease Obligation | $403,581 | $401,826 | $369,314 | $347,100 |
| Line Of Credit | $810,252 | $899,250 | $1,893,750 | $1,640,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,151,973 | $1,047,391 | $568,865 | - |
| Current Accrued Expenses | $2,055,175 | $2,073,611 | $1,872,573 | $1,300,803 |
| Dueto Related Parties Current | $773,045 | $173,493 | $359,992 | $393,424 |
| Duefrom Related Parties Non Current | $0 | $113,516 | $865,477 | $818,183 |
| Investments And Advances | $2,258,754 | $2,527,740 | $842,070 | $932,755 |
| Available For Sale Securities | $790,250 | $847,252 | $842,070 | - |
| Investmentsin Associatesat Cost | $1,468,504 | $1,680,488 | $0 | - |
| Net PPE | $1,151,475 | $1,378,561 | $1,735,119 | $1,997,780 |
| Accumulated Depreciation | $-3,341,739 | $-3,335,041 | $-3,304,457 | $-3,314,471 |
| Gross PPE | $4,493,214 | $4,713,602 | $5,039,576 | $5,312,251 |
| Other Properties | $640,387 | $809,283 | $1,161,141 | $1,471,899 |
| Machinery Furniture Equipment | $1,294,617 | $1,313,472 | $1,290,555 | $1,205,200 |
| Buildings And Improvements | $2,219,244 | $2,227,431 | $2,226,687 | $2,235,061 |
| Land And Improvements | $338,966 | $363,416 | $361,193 | $400,091 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $1,155,051 | $758,036 | $1,271,162 | $145,399 |
| Other Short Term Investments | $64,736 | $79,312 | $75,797 | $108,147 |
| Other Investments | - | $847,252 | $842,070 | - |
| Construction In Progress | - | $7,400,000 | $0 | - |
| Inventories Adjustments Allowances | - | - | $0 | $-155,370 |
| Finished Goods | - | - | $0 | $96,725 |
| Work In Process | - | - | $0 | $0 |
| Raw Materials | - | - | $0 | $84,620 |
| Goodwill | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-1,809,145 | $-4,208,049 | $-7,518,083 | $-7,615,222 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-1,809,145 | $-4,186,848 | $-7,398,391 | $-7,597,719 |
| Cash Flow From Continuing Operating Activities | $-1,809,145 | $-4,186,848 | $-7,398,391 | $-7,597,719 |
| Operating Gains Losses | $339,171 | $221,888 | - | $269,844 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $0 | $-360,186 | $-1,721,684 | $-805,966 |
| Cash Flow From Continuing Investing Activities | $0 | $-360,186 | $-1,721,684 | $-805,966 |
| Capital Expenditure | - | $-21,201 | $-119,692 | $-17,503 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-7,320 | $0 | - | - |
| Issuance Of Capital Stock | $31,040 | $1,050,000 | $3,663,925 | $11,119,452 |
| Financing Cash Flow | $1,980,769 | $3,869,961 | $4,013,925 | $9,995,550 |
| Cash Flow From Continuing Financing Activities | $1,980,769 | $3,869,961 | $4,013,925 | $9,995,550 |
| Net Other Financing Charges | $599,552 | $-48,999 | - | $-850,429 |
| Net Common Stock Issuance | $23,720 | $1,050,000 | $3,663,925 | $11,119,452 |
| Common Stock Issuance | $31,040 | $1,050,000 | $3,663,925 | $11,119,452 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-356,169 | $-1,000,000 | $0 | $-514,236 |
| Issuance Of Debt | $372,095 | $1,462,622 | $350,000 | $240,763 |
| Interest Paid Supplemental Data | $22,539 | $33,180 | $285,465 | $333,873 |
| Income Tax Paid Supplemental Data | $25,863 | $27,392 | $1,600 | $0 |
| End Cash Position | $863,815 | $716,780 | $1,391,728 | $6,565,215 |
| Beginning Cash Position | $716,780 | $1,391,728 | $6,565,215 | $5,001,371 |
| Effect Of Exchange Rate Changes | $-24,589 | $2,125 | $-67,337 | $-28,021 |
| Changes In Cash | $171,624 | $-677,073 | $-5,106,150 | $1,591,865 |
| Proceeds From Stock Option Exercised | $1,341,571 | $2,406,338 | $0 | - |
| Common Stock Payments | $-7,320 | $0 | - | - |
| Net Issuance Payments Of Debt | $15,926 | $462,622 | $350,000 | $-273,473 |
| Net Short Term Debt Issuance | $312,943 | $462,622 | $350,000 | $-95,735 |
| Short Term Debt Payments | $-29,152 | $-1,000,000 | $0 | $-100,000 |
| Short Term Debt Issuance | $342,095 | $1,462,622 | $350,000 | $4,265 |
| Net Long Term Debt Issuance | $-297,017 | $0 | $0 | $-177,738 |
| Long Term Debt Payments | $-327,017 | $0 | $0 | $-414,236 |
| Long Term Debt Issuance | $30,000 | $0 | $0 | $236,498 |
| Net Business Purchase And Sale | $0 | $-338,985 | $-1,601,992 | $-680,916 |
| Purchase Of Business | $0 | $-338,985 | $-1,601,992 | $-680,916 |
| Net PPE Purchase And Sale | $0 | $-21,201 | $-119,692 | $-17,503 |
| Purchase Of PPE | $0 | $-21,201 | $-119,692 | $-17,503 |
| Change In Working Capital | $-408,422 | $490,771 | $635,565 | $-1,613,761 |
| Change In Other Working Capital | $1,615 | $82,215 | $-2,600 | $-1,085 |
| Change In Other Current Liabilities | $-168,896 | $-351,859 | $-2,600 | - |
| Change In Payables And Accrued Expense | $39,873 | $751,708 | $1,851,253 | $-513,553 |
| Change In Accrued Expense | $152,819 | $638,762 | $1,608,784 | $-173,151 |
| Change In Payable | $-112,946 | $112,946 | $242,469 | $-340,402 |
| Change In Tax Payable | $-112,946 | $112,946 | $0 | - |
| Change In Income Tax Payable | $-112,946 | $112,946 | $0 | - |
| Change In Prepaid Assets | $12,948 | $101,926 | $238,092 | $-357,276 |
| Change In Receivables | $-293,962 | $-93,219 | $-1,451,180 | $-716,017 |
| Changes In Account Receivables | $0 | $228,557 | $-614,166 | $-120,980 |
| Other Non Cash Items | $532,769 | $1,244,245 | $32,350 | $-360,898 |
| Stock Based Compensation | $2,773,460 | $185,933 | $7,036,778 | $5,306,755 |
| Provisionand Write Offof Assets | $11,993 | $1,455,101 | $210,564 | $0 |
| Deferred Tax | $0 | $115,668 | $864,802 | $824,199 |
| Deferred Income Tax | $0 | $115,668 | $864,802 | $824,199 |
| Depreciation Amortization Depletion | $200,921 | $380,390 | $23,799 | $11,993 |
| Depreciation And Amortization | $200,921 | $380,390 | $23,799 | $11,993 |
| Depreciation | $200,921 | $380,390 | $23,799 | $11,993 |
| Gain Loss On Investment Securities | $339,171 | $221,888 | - | $269,844 |
| Net Income From Continuing Operations | $-5,259,037 | $-8,280,844 | $-16,312,374 | $-12,035,851 |
| Asset Impairment Charge | - | $0 | $110,125 | $0 |
| Net Investment Purchase And Sale | - | - | $0 | $-107,547 |
| Purchase Of Investment | - | - | $0 | $-107,547 |
| Change In Interest Payable | - | - | $-2,600 | $0 |
| Change In Account Payable | - | - | $0 | $-23,044 |
| Change In Inventory | - | - | $0 | $-25,830 |
| Sale Of Investment | - | - | - | $0 |